<DOC>
	<DOCNO>NCT02470234</DOCNO>
	<brief_summary>To assess pharmacokinetics single dose Aptensio XR® ( methylphenidate hydrochloride extended-release ) capsule fed condition male female child 4 6 year age ADHD .</brief_summary>
	<brief_title>Pharmacokinetic Study Methylphenidate HCl Extended-Release Capsules Children 4 Under 6 Years Age With ADHD</brief_title>
	<detailed_description>This multi-center , open-label , single-dose , study assess pharmacokinetics Aptensio XR® ( methylphenidate hydrochloride extended-release ) capsule male female child 4 6 year age ADHD feed condition . Screening Procedures : After obtain write informed consent parent , subject undergo complete medical medication history , demographic data ( include sex , age , race , ethnicity , body weight ( kg ) , height ( cm ) , Body Mass Index ( BMI ) ( kg/m2 ) , physical examination , vital sign evaluation ( sit blood pressure , pulse rate , respiration rate , temperature pulse oximetry ) , rest 12-lead electrocardiogram ( ECG ) , clinical laboratory test concomitant medication within 28 day prior receive study drug . On Day 1 : subject receive single oral dose Aptensio XR® .</detailed_description>
	<mesh_term>Attention Deficit Disorder Hyperactivity</mesh_term>
	<mesh_term>Methylphenidate</mesh_term>
	<criteria>1 . Patient male female age 4 6 year old . 2 . Patient history consistent ADHD , meet DSMIV criterion ADHD , inattentive , hyperactivity combine . 3 . Patient must meet criterion ADHD diagnosis KSADSPL clinical interview experience clinician ; symptom must present least 6 month . 4 . Subject prior behavioral treatment subject 's symptom severe enough warrant treatment without prior behavioral treatment , patient stable dose either immediaterelease extendedrelease methylphenidate . 5 . Subject must age sexadjusted rating ≥ 90th percentile Total Score ADHDRSIV Preschool Version , Clinical Global Impressions Severity Score ≥4 Child Global Assessment Scale rating &lt; 65 methylphenidate washout prior obtain pharmacokinetic sample . Ratings may complete via telephone day1 . 6 . Parents guardians patient must ability read understand language Informed Consent write mentally physically competent provide write informed consent child . 7 . Patient and/or parent are/is able understand English order provide assent otherwise able comply study protocol . 1 . Patient allergy methylphenidate amphetamine , history serious adverse reaction methylphenidate . 2 . Patient history tension , agitation , glaucoma , thyrotoxicosis , tachyarrythmias severe angina pectoris patient serious unstable medical illness asthma , diabetes seizure . 3 . A history motor vocal tic Tourette 's syndrome 4 . Patient receive MAO inhibitor , anticonvulsant ( phenobarbital , phenytoin , primidone ) , coumarin anticoagulant , presser agent , guanethidine , tricyclic antidepressant ( imipramine , desipramine , selective serotonin inhibitor ( SSRIs ) , herbal remedy ( e.g. , melatonin ) . 5 . Patient serious hypertension . 6 . Patient history disorder sensory organ , particularly deafness , severe profound retardation . 7 . Patient unstable psychiatric condition require treatment . 8 . Patient risk substance abuse . 9 . Evidence current physical , sexual , emotional abuse 10 . Living anyone currently abuse stimulant cocaine 11 . History bipolar disorder biological parent</criteria>
	<gender>All</gender>
	<minimum_age>4 Years</minimum_age>
	<maximum_age>5 Years</maximum_age>
	<verification_date>February 2016</verification_date>
	<keyword>ADHD</keyword>
	<keyword>Children</keyword>
	<keyword>Pharmacokinetics</keyword>
</DOC>